Nearly all of the clinical benefit in terms of reduced event rates in AFCAPS / TexCAPS
occurred in patients in the lowest third of HDL distribution at baseline, those with an HDL below 34 mg/dL.
In a hypothesis-generating analysis of the AFCAPS/ TexCAPS
trial published in 2001, lovastatin was found to benefit those with low LDL-C and high hsCRP, whereas no benefit was observed in low LDL-C, low hsCRP patients (10).
People in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS
) were most likely to have benefit from lovastatin if they had elevated CRP.
These aliquots were frozen and stored at -70[degrees]C at the AFCAPS/ TexCAPS